Supplier
Premier Medical, INC.
Premier Medical, INC. was paid $11.53M by Medicaid between Jan 2018 and Jun 2023, across 182 billing codes. Its largest line is 81406, — 13% of everything it billed.
33Billing provider infoPREMIER MEDICAL, INC.
GREENVILLE, SC 29616
GREENVILLE, SC 29616
33aNPI1689971822assigned 02/24/2011
33bProvider typeDurable Medical Equipment & Medical Supplies
28Total paid$11.53M
24GClaims637,905
24DCodes billed182
24AFirst – last monthJan 2018 – Jun 2023
Compared with peers
Next to other Durable Medical Equipment & Medical Supplies providers in South Carolina
Rank by total paid#2 of 160
Median peer was paid$125K
This provider vs. median92×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 347,886 | $4.64M | |
| 2019 | 86,905 | $3.75M | |
| 2020 | 80,710 | $1.30M | |
| 2021 | 51,937 | $922K | |
| 2022 | 62,718 | $828K | |
| 2023 | 7,749 | $91K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 81406 | 13% | 1,842 | 920 | $1.52M | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 9.2% | 15,138 | 7,969 | $1.07M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 7.9% | 20,543 | 10,587 | $907K |
| 81201 | 5.9% | 1,360 | 818 | $683K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 5.8% | 9,870 | 8,053 | $674K |
| 81298 | 5.8% | 1,046 | 664 | $671K | |
| 81317 | 5.4% | 1,357 | 816 | $624K | |
| 81404 | 4.9% | 1,479 | 909 | $570K | |
| 81321 | 4.7% | 1,050 | 666 | $543K | |
| 81292 | 4.5% | 1,050 | 663 | $519K | |
| 81405 | 4.3% | 1,458 | 907 | $499K | |
| 81295 | 3.7% | 1,052 | 664 | $428K |
170 more codes
| 81403 | 3.1% | 1,499 | $359K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.6% | 4,511 | $187K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.3% | 1,741 | $149K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 6,335 | $108K |
| 81432 | <1% | 302 | $107K | |
| 82172 | <1% | 8,109 | $81K | |
| 81479 | Unlisted molecular pathology procedure | <1% | 2,798 | $80K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 3,332 | $75K |
| 81408 | <1% | 1,361 | $71K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,925 | $68K |
| 83698 | <1% | 4,212 | $50K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,902 | $47K |
| 83090 | <1% | 6,165 | $44K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,131 | $38K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,084 | $37K |
| 86141 | <1% | 6,559 | $36K | |
| 80061 | Lipid panel | <1% | 9,927 | $35K |
| 84403 | <1% | 4,159 | $35K | |
| 84681 | <1% | 4,131 | $33K | |
| 82607 | <1% | 6,476 | $32K | |
| 86003 | <1% | 995 | $31K | |
| 82670 | <1% | 4,032 | $30K | |
| 81226 | <1% | 1,032 | $29K | |
| 83695 | <1% | 4,215 | $28K | |
| 83525 | <1% | 5,996 | $27K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 871 | $24K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,468 | $23K |
| 84144 | <1% | 3,305 | $23K | |
| 83001 | <1% | 3,327 | $23K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 1,501 | $23K |
| 83701 | <1% | 2,180 | $22K | |
| 82627 | <1% | 2,668 | $21K | |
| 82746 | <1% | 4,634 | $21K | |
| 84481 | <1% | 5,698 | $19K | |
| 87640 | <1% | 2,476 | $19K | |
| 87486 | <1% | 2,129 | $19K | |
| 87581 | <1% | 2,126 | $19K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,138 | $19K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 588 | $18K |
| 84146 | <1% | 2,687 | $18K | |
| 84270 | <1% | 2,321 | $18K | |
| 87631 | <1% | 367 | $18K | |
| 80053 | Comprehensive metabolic panel | <1% | 4,409 | $18K |
| 83002 | <1% | 2,663 | $17K | |
| 81225 | <1% | 1,041 | $17K | |
| 87541 | <1% | 1,480 | $17K | |
| 83970 | <1% | 1,643 | $17K | |
| 87498 | <1% | 1,458 | $17K | |
| 86800 | <1% | 3,310 | $17K | |
| 86376 | <1% | 3,350 | $16K | |
| 87634 | <1% | 880 | $15K | |
| 80346 | <1% | 10,408 | $15K | |
| 84466 | <1% | 3,399 | $13K | |
| 84550 | <1% | 6,725 | $13K | |
| 80355 | <1% | 10,800 | $13K | |
| 81401 | <1% | 1,088 | $12K | |
| 84378 | <1% | 1,872 | $12K | |
| 80361 | <1% | 10,411 | $12K | |
| 80366 | <1% | 10,799 | $11K | |
| 80363 | <1% | 10,409 | $11K | |
| 84439 | <1% | 3,237 | $11K | |
| 80356 | <1% | 10,405 | $11K | |
| 83704 | <1% | 709 | $11K | |
| 83876 | <1% | 1,124 | $10K | |
| 81227 | <1% | 1,038 | $10K | |
| 81002 | <1% | 12,854 | $10K | |
| 80369 | <1% | 10,447 | $10K | |
| 81162 | <1% | 252 | $10K | |
| 80372 | <1% | 10,410 | $10K | |
| 80373 | <1% | 10,415 | $10K | |
| 80368 | <1% | 9,946 | $10K | |
| 83735 | <1% | 3,171 | $10K | |
| 80325 | <1% | 10,407 | $9K | |
| 80321 | <1% | 9,870 | $9K | |
| 80367 | <1% | 9,953 | $9K | |
| 80357 | <1% | 9,817 | $9K | |
| 82977 | <1% | 3,917 | $9K | |
| 80371 | <1% | 9,938 | $9K | |
| 80354 | <1% | 10,409 | $9K | |
| 81231 | <1% | 1,029 | $8K | |
| 80365 | <1% | 10,405 | $8K | |
| 83540 | <1% | 3,211 | $8K | |
| 80359 | <1% | 10,405 | $8K | |
| 80348 | <1% | 10,411 | $8K | |
| 81230 | <1% | 1,027 | $8K | |
| 80360 | <1% | 9,950 | $8K | |
| 80320 | <1% | 8,957 | $8K | |
| 83992 | <1% | 10,459 | $7K | |
| 82728 | <1% | 2,237 | $7K | |
| 83550 | <1% | 2,337 | $7K | |
| 80353 | <1% | 10,405 | $6K | |
| 81328 | <1% | 907 | $6K | |
| 81241 | <1% | 983 | $6K | |
| 84436 | <1% | 5,715 | $6K | |
| 81291 | <1% | 1,013 | $6K | |
| 80349 | <1% | 5,176 | $6K | |
| 81242 | <1% | 306 | $5K | |
| 81240 | <1% | 980 | $5K | |
| 80358 | <1% | 10,443 | $5K | |
| 82533 | <1% | 1,890 | $5K | |
| 80337 | <1% | 7,613 | $5K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 325 | $4K |
| 87653 | <1% | 1,027 | $4K | |
| 81355 | <1% | 965 | $4K | |
| 84450 | <1% | 2,772 | $4K | |
| 82565 | <1% | 2,542 | $4K | |
| 84075 | <1% | 2,766 | $4K | |
| 82310 | <1% | 2,500 | $3K | |
| 84153 | <1% | 520 | $3K | |
| 82947 | <1% | 2,553 | $3K | |
| 82247 | <1% | 2,355 | $3K | |
| 82570 | <1% | 12,994 | $3K | |
| 84520 | <1% | 2,532 | $3K | |
| 86803 | <1% | 306 | $2K | |
| 87481 | <1% | 1,089 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,135 | $2K |
| 82785 | <1% | 363 | $2K | |
| 82248 | <1% | 1,772 | $2K | |
| 84402 | <1% | 411 | $2K | |
| 87340 | <1% | 282 | $2K | |
| 86704 | <1% | 223 | $1K | |
| 86709 | <1% | 216 | $1K | |
| 87511 | <1% | 1,115 | $1K | |
| 84479 | <1% | 3,573 | $1K | |
| 83986 | <1% | 12,708 | $1K | |
| 84460 | <1% | 1,367 | $1K | |
| 82040 | <1% | 1,366 | $972.97 | |
| 82374 | <1% | 1,124 | $896.16 | |
| 84295 | <1% | 1,102 | $891.96 | |
| 84132 | <1% | 1,174 | $885.95 | |
| 82435 | <1% | 1,122 | $859.90 | |
| 86592 | <1% | 259 | $672.41 | |
| 99000 | <1% | 3,398 | $650.46 | |
| 84155 | <1% | 1,045 | $631.84 | |
| 86593 | <1% | 190 | $611.99 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 517 | $490.11 |
| 80334 | <1% | 2,230 | $478.96 | |
| 83718 | <1% | 201 | $383.56 | |
| 84480 | <1% | 1,353 | $373.81 | |
| 83719 | <1% | 353 | $370.99 | |
| 85652 | <1% | 293 | $366.46 | |
| 83690 | <1% | 498 | $263.98 | |
| 82150 | <1% | 498 | $248.26 | |
| 84484 | <1% | 25 | $200.00 | |
| 84478 | <1% | 204 | $170.81 | |
| 82465 | <1% | 223 | $153.79 | |
| 82664 | <1% | 181 | $140.36 | |
| 82043 | <1% | 25 | $120.00 | |
| 81001 | <1% | 712 | $118.42 | |
| 80374 | <1% | 140 | $112.49 | |
| 85027 | <1% | 65 | $109.77 | |
| 83520 | <1% | 24 | $105.96 | |
| 86762 | <1% | 17 | $102.75 | |
| 80050 | General health panel | <1% | 71 | $82.96 |
| 80076 | <1% | 101 | $71.98 | |
| P9615 | Catheterization for collection of specimen(s) (multiple patients) | <1% | 12 | $68.64 |
| 83516 | <1% | 199 | $63.59 | |
| 87276 | <1% | 15 | $50.17 | |
| 84100 | <1% | 196 | $47.60 | |
| 87275 | <1% | 15 | $46.49 | |
| 82550 | <1% | 131 | $44.54 | |
| 86140 | <1% | 25 | $43.59 | |
| 84154 | <1% | 43 | $40.15 | |
| 85007 | <1% | 55 | $36.42 | |
| 86317 | <1% | 23 | $10.23 | |
| 87535 | 0% | 62 | $0.00 | |
| 86702 | 0% | 62 | $0.00 | |
| 86701 | 0% | 62 | $0.00 | |
| 81015 | 0% | 80 | $0.00 | |
| 80345 | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMURDOCK, KEVIN (CEO)